Leishmaniasis chemotherapy—challenges and opportunities
TLDR
There remain challenges to ensure that treatments effective in India are also effective in other regions of the world and to identify treatment for post kala-azar dermal leishmaniasis as well as the opportunity to develop a safe oral short-course treatment.About:
This article is published in Clinical Microbiology and Infection.The article was published on 2011-10-01 and is currently open access. It has received 375 citations till now. The article focuses on the topics: Cutaneous leishmaniasis & Visceral leishmaniasis.read more
Citations
More filters
Journal ArticleDOI
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Alicia Ponte-Sucre,Francisco Gamarro,Jean-Claude Dujardin,Michael P. Barrett,Rogelio López-Vélez,Raquel García-Hernández,Andrew W. Pountain,Roy Mwenechanya,Barbara Papadopoulou +8 more
TL;DR: The meaning of “resistance” related to leishmaniasis and its molecular epidemiology are discussed, particularly for Leishmania donovani that causes visceral leish maniasis, and how resistance can affect drug combination therapies are discussed.
Journal ArticleDOI
Management of trypanosomiasis and leishmaniasis
TL;DR: Clinical studies with benznidazole, a drug previously recommended only for acute stage treatment, are close to completion to determine the effectiveness in the treatment of early chronic and indeterminate Chagas disease.
Journal ArticleDOI
Advances in Development of New Treatment for Leishmaniasis.
Juliana Perrone Bezerra de Menezes,Carlos Eduardo Sampaio Guedes,Antonio Luis de Oliveira Almeida Petersen,Deborah Bittencourt Mothé Fraga,Patrícia Sampaio Tavares Veras +4 more
TL;DR: How high-throughput analysis is helping the scientific community to identify novel targets for chemotherapeutic interventions and how this helped to identify and assess the potential of new identified targets is discussed.
Journal ArticleDOI
Adaptive mechanisms in pathogens: universal aneuploidy in Leishmania
TL;DR: Several reports revealed extensive variation in chromosome copy number, indicating that aneuploidy is a constitutive feature of this protozoan parasite genus.
Journal ArticleDOI
Novel insights into genome plasticity in Eukaryotes: mosaic aneuploidy in Leishmania
TL;DR: First, mosaic aneuploidy might be considered as a powerful strategy evolved by the parasite for adapting to modifications of environment conditions as well as for the emergence of drug resistance.
References
More filters
Journal ArticleDOI
Drug Resistance in Leishmaniasis
TL;DR: It is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.
Journal ArticleDOI
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Jorge Alvar,Pilar Aparicio,Abraham Aseffa,Margriet den Boer,Carmen Cañavate,Jean-Pierre Dedet,Luigi Gradoni,Rachel ter Horst,Rogelio López-Vélez,Javier Moreno +9 more
TL;DR: Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.
Journal ArticleDOI
Oral Miltefosine for Indian Visceral Leishmaniasis
Shyam Sundar,T. K. Jha,Thakur Cp,Juergen Engel,Herbert Sindermann,Christina Fischer,Klaus Junge,Anthony Bryceson,Jonathan Berman +8 more
TL;DR: Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis and may also be helpful in regions where parasites are resistant to current agents.
Journal ArticleDOI
Drug resistance in Indian visceral leishmaniasis.
TL;DR: Despite several disadvantages, amphotericin B is the only drug available for use in these areas and should be used as first‐line drug instead of Sbv, and the new oral antileishmanial drug miltefosine is likely to be the first-line drug in future.
Journal ArticleDOI
Injectable paromomycin for Visceral leishmaniasis in India.
TL;DR: A randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care for the treatment of visceral leishmaniasis in Bihar, India, showed parmomycin was shown to be noninferior to amphoteric in B.